SurvivorNet on MSN
The evERA Trial: A Promising Treatment Option For Patients With Estrogen Receptor-Positive (ER+), HER2-Negative (HER2-) Breast Cancer
The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...
MedPage Today on MSN
For your patients: What to know about the newest treatments for HR+/HER2- breast cancer
The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors combined with endocrine therapy (ET). This dual-therapy targets a pathway ...
Most types of breast cancer produce similar symptoms and are discovered the same way—finding a strange new lump during a self-exam, or a healthcare provider spotting something suspicious during a ...
On August 8, 2025, the FDA granted accelerated approval to zongertinib for adult patients with unresectable or metastatic ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...
If your oncologist has talked to you about antibody-drug conjugates (ADC) to treat HR-positive/HER2-negative metastatic breast cancer, you’ve likely already tried ...
Our top 5 highlights from the 2025 San Antonio Breast Cancer Symposium (SABCS) include articles and interviews introducing ...
“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Now, if ever there ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback